What Is Genuinely Working
The year ended better than it began. Organic growth improved during the second half, and every region returned to positive organic growth in Q4. That is a useful directional signal, although it did not lift full-year organic growth above zero. Presentation pp. 6–7
Fit4Growth includes tangible actions. Amplifon closed about 160 underperforming hearing centres, reduced capital expenditure by €30M, and began simplifying its network and back office. The annual report discloses an overall headcount reduction of about 230 employees. Annual Report p. 30
Cash generation and liquidity remain meaningful. Adjusted free cash flow was €174.4M and the company reported roughly €1.2B of liquidity headroom with no financial covenants from June 2025. Annual Report pp. 31, 72–73
Americas underlying sales grew despite currency pressure. Americas organic growth was 1.9%, even though reported revenue fell 2.3% as foreign exchange reduced growth by 6.3%. Annual Report pp. 54–55
Regional Scorecard
| Region | Reported | Organic | Adj. margin | View |
|---|---|---|---|---|
| EMEA | +1.5% | −0.6% | 26.6% | Scale, weak core |
| Americas | −2.3% | +1.9% | 23.5% | FX pressure |
| APAC | −6.8% | −0.3% | 24.9% | Weakest |
Adjusted EBITDA declined in all three regions, and each regional adjusted margin was lower than in 2024. Annual Report pp. 56–59
What The Headline Obscures
Growth came from perimeter changes, not the existing business. Revenue rose 1.7% at constant exchange rates, but organic growth was flat. Acquisitions and perimeter effects added 1.7%, while foreign exchange subtracted 2.3%, leaving reported revenue down 0.6%. Presentation pp. 3, 6
Weakness was not limited to accounting adjustments. Reported EBITDA fell 8.8% and reported group profit fell 37.2%; adjusted EBITDA still fell 4.5% and adjusted group profit fell 15.4%. Annual Report p. 30
Free cash flow declined and capex cuts helped support it. Adjusted free cash flow fell €7.6M to €174.4M, while reported free cash flow fell €15.9M to €159.9M. Adjusted operating cash flow fell €35.9M before lower capital expenditure partly offset the decline. Presentation p. 13
Capital returns coincided with rising leverage. Net debt excluding leases increased €83.7M to €1,045.5M and leverage rose from 1.63x to 1.92x. During the year Amplifon spent €108.2M on buybacks, €65.3M on dividends, and €62.3M on acquisitions. Annual Report pp. 31–32
Corporate Language, Decoded
What To Watch Next
Bull case: The positive Q4 organic trend persists, Fit4Growth converts closures and cost reductions into sustained margin recovery, and Americas growth offsets soft EMEA and APAC demand.
Bear case: Organic growth remains below the roughly 3% market-growth assumption, restructuring benefits arrive late, and buybacks or acquisitions keep leverage elevated while earnings remain under pressure.
Measurable watchlist: Organic growth versus the market assumption; adjusted and reported EBITDA margins; performance by region; adjusted free cash flow before capex reductions; net debt and leverage; delivery against the high end of the 150–200 bps Fit4Growth run-rate margin target by 2027. Management described 2026 profitability improvement qualitatively but did not provide a specific 2026 margin target. Annual Report p. 90